Back to top
more

Collegium Pharmaceutical (COLL)

(Delayed Data from NSDQ)

$36.71 USD

36.71
219,512

+0.29 (0.80%)

Updated Apr 29, 2024 04:00 PM ET

After-Market: $36.73 +0.02 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Ironwood (IRWD) Q4 Earnings Miss, Linzess Volume Grows

Ironwood (IRWD) witnesses flat year-over-year sales growth. Its fourth-quarter earnings miss estimates. The company maintains revenue guidance for 2022. Stock declines.

Has Aytu BioPharma Inc. (AYTU) Outpaced Other Medical Stocks This Year?

Here is how Aytu BioPharma Inc. (AYTU) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.

Biotech Stock Roundup: BDSI Surges on Merger Deal, SGEN Down on Outlook & More

Merger updates from BioDelivery (BDSI) and Seagen (SGEN) earnings results are among a few key highlights from the biotech sector during the past week.

BioDelivery (BDSI) Stock Surges on Buyout Offer From Collegium

Collegium (COLL) is set to acquire BioDelivery (BDSI) for approximately $604 million in cash. The transaction is likely to be completed by the end of first-quarter 2022.

Collegium Pharmaceutical (COLL) Misses Q3 Earnings and Revenue Estimates

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -76.09% and -6.31%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Rimmi Singhi headshot

6 High Earnings Yield Picks That You Shouldn't Miss Out On

Reap handsome rewards by investing in high earnings yield stocks including MT, MTH, SIMO, DFIN, IRWD, and COLL.

Enlivex (ENLV) Begins Phase IIb COVID-19 Study on Cell Therapy

Enlivex (ENLV) doses the first patient in a phase IIb study evaluating its cell therapy, Allocetra, in severe and critical COVID-19 patients with acute respiratory distress syndrome.

COLL vs. ZTS: Which Stock Should Value Investors Buy Now?

COLL vs. ZTS: Which Stock Is the Better Value Option?

Collegium Pharmaceutical (COLL) Q2 Earnings and Revenues Miss Estimates

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -20.59% and -1.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Collegium Pharmaceutical (COLL) Beats Q1 Earnings and Revenue Estimates

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 36.67% and 8.01%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Collegium Pharmaceutical (COLL) Reports Next Week: Wall Street Expects Earnings Growth

Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Collegium Pharmaceutical (COLL) Tops Q3 Earnings and Revenue Estimates

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 39.13% and 1.61%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Collegium Pharmaceutical (COLL) Q2 Earnings Miss Estimates

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -4.17% and 4.26%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AMRX vs. COLL: Which Stock Should Value Investors Buy Now?

AMRX vs. COLL: Which Stock Is the Better Value Option?

AMRX vs. COLL: Which Stock Should Value Investors Buy Now?

AMRX vs. COLL: Which Stock Is the Better Value Option?

AMRX or COLL: Which Is the Better Value Stock Right Now?

AMRX vs. COLL: Which Stock Is the Better Value Option?

AMRX or COLL: Which Is the Better Value Stock Right Now?

AMRX vs. COLL: Which Stock Is the Better Value Option?

Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Top Ranked Growth Stocks to Buy for April 6th

Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, April 6th

Top Ranked Growth Stocks to Buy for April 1st

Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, April 1st

COLL or NBIX: Which Is the Better Value Stock Right Now?

COLL vs. NBIX: Which Stock Is the Better Value Option?